1. Home
  2. OPAD vs FEMY Comparison

OPAD vs FEMY Comparison

Compare OPAD & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OPAD

Offerpad Solutions Inc.

N/A

Current Price

$0.79

Market Cap

35.5M

Sector

Finance

ML Signal

N/A

Logo Femasys Inc.

FEMY

Femasys Inc.

N/A

Current Price

$0.57

Market Cap

37.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPAD
FEMY
Founded
2015
2004
Country
United States
United States
Employees
140
N/A
Industry
Real Estate
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
37.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OPAD
FEMY
Price
$0.79
$0.57
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$1.83
$5.50
AVG Volume (30 Days)
1.1M
407.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
8.60
EPS
N/A
N/A
Revenue
N/A
$1,629,108.00
Revenue This Year
N/A
$64.02
Revenue Next Year
$32.08
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.97
52 Week Low
$0.71
$0.31
52 Week High
$6.35
$1.76

Technical Indicators

Market Signals
Indicator
OPAD
FEMY
Relative Strength Index (RSI) 41.27 54.51
Support Level $0.71 $0.54
Resistance Level $0.90 $0.58
Average True Range (ATR) 0.06 0.03
MACD 0.02 0.01
Stochastic Oscillator 44.44 81.38

Price Performance

Historical Comparison
OPAD
FEMY

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services, including mortgage, listing, renovation, and buyer representation services.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: